{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:15:14Z","timestamp":1791249314607,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2006,5,4]],"date-time":"2006-05-04T00:00:00Z","timestamp":1146700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,5,4]],"date-time":"2006-05-04T00:00:00Z","timestamp":1146700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2006,9,1]]},"DOI":"10.1038\/sj.gt.3302756","type":"journal-article","created":{"date-parts":[[2006,5,4]],"date-time":"2006-05-04T10:23:49Z","timestamp":1146738229000},"page":"1263-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"R","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L-J","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-M","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-J","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-C","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-Q","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,5,4]]},"reference":[{"key":"BF3302756_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/annonc\/mdf093","volume":"13","author":"RS Kerbel","year":"2002","unstructured":"Kerbel RS, Klement G, Pritchard KI, Kamen B . Continuous low-dose anti-angiogenic\/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12\u201315.","journal-title":"Ann Oncol"},{"key":"BF3302756_CR2","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1200\/JCO.2000.18.16.2935","volume":"18","author":"BA Kamen","year":"2000","unstructured":"Kamen BA, Rubin E, Aisner J, Glatstein E . High-time chemotherapy or high time for low dose. J Clin Oncol 2000; 18: 2935\u20132937.","journal-title":"J Clin Oncol"},{"key":"BF3302756_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(01)00587-3","volume":"2","author":"G Gasparini","year":"2001","unstructured":"Gasparini G . Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2: 733\u2013740.","journal-title":"Lancet Oncol"},{"key":"BF3302756_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/37126","volume":"390","author":"T Boehm","year":"1997","unstructured":"Boehm T, Folkman J, Browder T, O'Reilly MS . Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404\u2013407.","journal-title":"Nature"},{"key":"BF3302756_CR5","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","volume":"105","author":"G Klement","year":"2000","unstructured":"Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15\u2013R24.","journal-title":"J Clin Invest"},{"key":"BF3302756_CR6","first-page":"6938","volume":"62","author":"G Bocci","year":"2002","unstructured":"Bocci G, Nicolaou KC, Kerbel RS . Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938\u20136943.","journal-title":"Cancer Res"},{"key":"BF3302756_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/bies.950130106","volume":"13","author":"RS Kerbel","year":"1991","unstructured":"Kerbel RS . Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991; 13: 31\u201336.","journal-title":"BioEssays"},{"key":"BF3302756_CR8","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878\u20131886.","journal-title":"Cancer Res"},{"key":"BF3302756_CR9","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","volume":"333","author":"J Folkman","year":"1995","unstructured":"Folkman J . Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757\u20131763.","journal-title":"N Engl J Med"},{"key":"BF3302756_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-3-642-45769-2_33","volume":"152","author":"AL Harris","year":"1998","unstructured":"Harris AL . Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Res Cancer Res 1998; 152: 341\u2013352.","journal-title":"Recent Res Cancer Res"},{"key":"BF3302756_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1005710426406","volume":"15","author":"SG Eckhardt","year":"1997","unstructured":"Eckhardt SG, Pluda JM . Development of angiogenesis inhibitors for cancer therapy. Invest New Drug 1997; 15: 1\u20133.","journal-title":"Invest New Drug"},{"key":"BF3302756_CR12","first-page":"S127","volume":"2","author":"J Folkman","year":"2003","unstructured":"Folkman J . Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2: S127\u2013S133.","journal-title":"Cancer Biol Ther"},{"key":"BF3302756_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1479-5876-2-22","volume":"2","author":"A Tandle","year":"2004","unstructured":"Tandle A, Blazer DG, Libutti SK . Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2004; 2: 22.","journal-title":"J Transl Med"},{"key":"BF3302756_CR14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V90.3.909","volume":"90","author":"BJ Rollins","year":"1997","unstructured":"Rollins BJ . Chemokines. Blood 1997; 90: 909\u2013928.","journal-title":"Blood"},{"key":"BF3302756_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","volume":"18","author":"D Rossi","year":"2000","unstructured":"Rossi D, Zlotnik A . The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217\u2013242.","journal-title":"Annu Rev Immunol"},{"key":"BF3302756_CR16","doi-asserted-by":"publisher","first-page":"27348","DOI":"10.1074\/jbc.270.45.27348","volume":"270","author":"RM Strieter","year":"1995","unstructured":"Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348\u201327357.","journal-title":"J Biol Chem"},{"key":"BF3302756_CR17","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood.V89.8.2635","volume":"89","author":"C Sgadari","year":"1997","unstructured":"Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR et al. Mig, the monokine induced by interferon-\u03b3, promotes tumor necrosis in vivo. Blood 1997; 89: 2635\u20132643.","journal-title":"Blood"},{"key":"BF3302756_CR18","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.4049\/jimmunol.162.8.4928","volume":"162","author":"S Gasperini","year":"1999","unstructured":"Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H et al. Gene expression and production of the monokine induced by IFN-\u03b3 (MIG), IFN-inducible T cell-chemoattractant (I-TAC), and IFN-\u03b3 inducible protein-10(IP-10) chemokines by human neutrophils. J Immunol 1999; 162: 4928\u20134937.","journal-title":"J Immunol"},{"key":"BF3302756_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.182.5.1301","volume":"182","author":"F Liao","year":"1995","unstructured":"Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM . Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182: 1301\u20131314.","journal-title":"J Exp Med"},{"key":"BF3302756_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1126\/science.301.5632.452","volume":"301","author":"J Marx","year":"2003","unstructured":"Marx J . Angiogenesis: a boost for tumor starvation. Science 2003; 301: 452\u2013454.","journal-title":"Science"},{"key":"BF3302756_CR21","first-page":"7669","volume":"61","author":"O Kisker","year":"2001","unstructured":"Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669\u20137674.","journal-title":"Cancer Res"},{"key":"BF3302756_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.cgt.7700266","volume":"7","author":"RJ Jin","year":"2000","unstructured":"Jin RJ, Kwak C, Lee SG, Lee CH, Soo CG, Park MS et al. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther 2000; 7: 1537\u20131542.","journal-title":"Cancer Gene Ther"},{"key":"BF3302756_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jnci\/87.8.581","volume":"87","author":"EE Voest","year":"1995","unstructured":"Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J . Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995; 87: 581\u2013586.","journal-title":"J Natl Cancer Inst"},{"key":"BF3302756_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-2004-831051","volume":"30","author":"A Bikfalvi","year":"2004","unstructured":"Bikfalvi A, Gimenez-Gallego G . The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost 2004; 30: 137\u2013144.","journal-title":"Semin Thromb Hemost"},{"key":"BF3302756_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ijc.10292","volume":"99","author":"AL Feldman","year":"2002","unstructured":"Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99: 149\u2013153.","journal-title":"Int J Cancer"},{"key":"BF3302756_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/10430340050015996","volume":"11","author":"CL Addison","year":"2000","unstructured":"Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS et al. The CXC chemokine, monokine induced by interferon-\u03b3, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 2000; 11: 247\u2013261.","journal-title":"Hum Gene Ther"},{"key":"BF3302756_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1749-6632.1996.tb52664.x","volume":"795","author":"AL Angiolillo","year":"1996","unstructured":"Angiolillo AL, Sgadari C, Tosato G . A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 1996; 795: 158\u2013167.","journal-title":"Ann NY Acad Sci"},{"key":"BF3302756_CR28","doi-asserted-by":"publisher","first-page":"8205","DOI":"10.1073\/pnas.95.14.8205","volume":"95","author":"H Soto","year":"1998","unstructured":"Soto H, Wang W, Strieter RM, Copeland NG, Gilbert DJ, Jenkins NA et al. The CC chemokine 6-Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 1998; 95: 8205\u20138210.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302756_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1084\/jem.184.3.963","volume":"184","author":"M Loetscher","year":"1996","unstructured":"Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP-10 and MIG: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963\u2013969.","journal-title":"J Exp Med"},{"key":"BF3302756_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/jlb.61.3.246","volume":"61","author":"JM Farber","year":"1997","unstructured":"Farber JM . Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246\u2013257.","journal-title":"J Leukoc Biol"},{"key":"BF3302756_CR31","first-page":"1388","volume":"60","author":"A Eberhard","year":"2000","unstructured":"Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388\u20131393.","journal-title":"Cancer Res"},{"key":"BF3302756_CR32","first-page":"7501","volume":"61","author":"L Bello","year":"2001","unstructured":"Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F et al. Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo. Cancer Res 2001; 61: 7501\u20137506.","journal-title":"Cancer Res"},{"key":"BF3302756_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000087303","volume":"69","author":"JM Hou","year":"2005","unstructured":"Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY et al. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 2005; 69: 81\u201387.","journal-title":"Oncology"},{"key":"BF3302756_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1044-579X(02)00133-5","volume":"13","author":"J Folkman","year":"2003","unstructured":"Folkman J . Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159\u2013167.","journal-title":"Semin Cancer Biol"},{"key":"BF3302756_CR35","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1089\/hum.2005.16.1075","volume":"16","author":"B Yao","year":"2005","unstructured":"Yao B, He QM, Tian L, Xiao F, Jiang Y, Zhang R et al. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. Hum Gene Ther 2005; 16: 1075\u20131086.","journal-title":"Hum Gene Ther"},{"key":"BF3302756_CR36","first-page":"963","volume":"57","author":"M Relf","year":"1997","unstructured":"Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R et al. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963\u2013969.","journal-title":"Cancer Res"},{"key":"BF3302756_CR37","first-page":"8498","volume":"61","author":"JM Ruehlmann","year":"2001","unstructured":"Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Pertl U, Dolman CS et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001; 61: 8498\u20138503.","journal-title":"Cancer Res"},{"key":"BF3302756_CR38","first-page":"8408","volume":"63","author":"IF Hermans","year":"2003","unstructured":"Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V . Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63: 8408\u20138413.","journal-title":"Cancer Res"},{"key":"BF3302756_CR39","doi-asserted-by":"publisher","first-page":"11545","DOI":"10.1073\/pnas.191112198","volume":"98","author":"YQ Wei","year":"2001","unstructured":"Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y et al. Immunogene therapy of tumors with vaccine based on xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001; 98: 11545\u201311550.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302756_CR40","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.gt.3301788","volume":"9","author":"F Xiao","year":"2002","unstructured":"Xiao F, Wei Y, Yang L, Zhao X, Tian L, Ding Z et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Therapy 2002; 9: 1207\u20131213.","journal-title":"Gene Therapy"},{"key":"BF3302756_CR41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.4049\/jimmunol.172.2.1132","volume":"172","author":"F McAllister","year":"2004","unstructured":"McAllister F, Steele C, Zheng M, Young E, Shellito JE, Marrero L et al. T cytotoxic-1 CD8+ T Cells are effector cells against pneumocystis in mice. J Immunol 2004; 172: 1132\u20131138.","journal-title":"J Immunol"},{"key":"BF3302756_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/ijc.20449","volume":"112","author":"GH Tan","year":"2004","unstructured":"Tan GH, Tian L, Wei YQ, Zhao X, Li J, Wu Y et al. Combinaton of low-dose cisplatin and recombination xenogeheic endoglin as a vaccin induses synergistic antitumor activities. Int J Cancer 2004; 112: 701\u2013706.","journal-title":"Int J Cancer"},{"key":"BF3302756_CR43","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1016\/S0959-8049(00)00345-2","volume":"36","author":"CJ Moorsel","year":"2000","unstructured":"Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. Eur J Cancer 2000; 36: 2420\u20132429.","journal-title":"Eur J Cancer"},{"key":"BF3302756_CR44","doi-asserted-by":"publisher","first-page":"21831","DOI":"10.1074\/jbc.M300880200","volume":"278","author":"QM He","year":"2003","unstructured":"He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003; 278: 21831\u201321836.","journal-title":"J Biol Chem"},{"key":"BF3302756_CR45","first-page":"3847","volume":"57","author":"J Hoffmann","year":"1997","unstructured":"Hoffmann J, Schirner M, Menrad A, Schneider MR . A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 1997; 57: 3847\u20133851.","journal-title":"Cancer Res"},{"key":"BF3302756_CR46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/80506","volume":"6","author":"YQ Wei","year":"2000","unstructured":"Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160\u20131166.","journal-title":"Nat Med"},{"key":"BF3302756_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1006\/mvre.1999.2233","volume":"59","author":"R Wild","year":"2000","unstructured":"Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW . Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000; 59: 368\u2013376.","journal-title":"Microvasc Res"},{"key":"BF3302756_CR48","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.95.16.9482","volume":"95","author":"RC Fields","year":"1998","unstructured":"Fields RC, Shimizu K, Mule JJ . Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482\u20139487.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF3302756_CR49","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.4049\/jimmunol.170.6.3162","volume":"170","author":"Y Lu","year":"2003","unstructured":"Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor1. J Immunol 2003; 170: 3162\u20133170.","journal-title":"J Immunol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/3302756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302756","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302756.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:15:28Z","timestamp":1683450928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/3302756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,4]]},"references-count":49,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2006,9,1]]}},"alternative-id":["BF3302756"],"URL":"https:\/\/doi.org\/10.1038\/sj.gt.3302756","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,4]]},"assertion":[{"value":"3 March 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}